1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine 923-61-5

1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine

Hexadecanoic acid,1,1′-[(1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl] ester;Palmitin,1,2-di-,2-aminoethyl hydrogen phosphate,L-;Hexadecanoic acid,1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester,(R)-;Hexadecanoic acid,(1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester;Dipalmitoyl-L-α-cephalin;1,2-Dipalmitoyl-L-3-phosphatidylethanolamine;1,2-Dipalmitoylglycerophosphorylethanolamine;Dipalmitoyl-L-α-phosphatidylethanolamine;1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine;L-β,γ-Dipalmitoyl-α-phosphatidylethanolamine;1,2-Dipalmitoyl-sn-glycerol-3-phosphoethanolamine;L-α-Dipalmitoylphosphatidylethanolamine;1,2-Dipalmitoyl-3-sn-phosphatidylethanolamine;1,2-Dihexadecanoyl-sn-glycerol-3-phosphorylethanolamine;sn-1,2-dipalmitoylglycerophosphoethanolamine;1,2-Dipalmitoyl-sn-glycerol-3-L-α-phosphorylethanolamine;1,2-Dipalmitoyl-L-α-phosphatidylethanolamine;1,2-Dipalmitoyl-sn-glycerophosphoethanolamine;1,2-Dipalmitoyl-sn-glycerol-3-phosphorylethanolamine;1,2-Dipalmitoyl-sn-glycero-3-phosphatidylethanolamine;1,2-Dipalmitoyl-sn-glycero-3-phosphatidylethanolamine;(R)-Dipalmitoylphosphatidylethanolamine;DPPE;Coatsome ME 6060;DHPE;1,2-Dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine;2-Azaniumylethyl [(2R)-2,3-di(hexadecanoyloxy)propyl] phosphate;81064-60-0;157837-95-1

923-61-5

C37H74NO8P

InChIKey=SLKDGVPOSSLUAI-PGUFJCEWSA-N

691.972

691.96

213-097-1

4FWH120Z1Z

2931900090

Bulk Drug Intermediates

134

13.70

Solid

1.01g/cm3

190-191 °C

723.6±70.0 °C at 760 mmHg

391.4±35.7 °C

1.473

-20ºC

262.5 Ų [M-H]-

Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator

Research compound — Not FDA approved

A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.

65 pM

Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).

Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.

NCT04488419

PubChem

9WYX65A5C2

Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status

Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.